Ritholtz Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.5M Buy
49,487
+1,552
+3% +$334K 0.19% 66
2026
Q1
$10.4M Buy
47,935
+487
+1% +$108K 0.18% 68
2025
Q4
$10.8M Buy
47,448
+3,723
+9% +$848K 0.2% 57
2025
Q3
$10.1M Buy
43,725
+2,113
+5% +$430K 0.2% 58
2025
Q2
$7.72M Buy
41,612
+1,877
+5% +$349K 0.17% 69
2025
Q1
$8.33M Buy
39,735
+1,433
+4% +$279K 0.25% 56
2024
Q4
$6.81M Buy
38,302
+245
+0.6% +$45K 0.2% 63
2024
Q3
$7.52M Sell
38,057
-804
-2% -$150K 0.23% 57
2024
Q2
$6.67M Sell
38,861
-327
-0.8% -$54.2K 0.22% 58
2024
Q1
$7.14M Buy
39,188
+2,817
+8% +$485K 0.25% 53
2023
Q4
$5.64M Sell
36,371
-3,986
-10% -$581K 0.22% 54
2023
Q3
$6.02M Buy
40,357
+5,800
+17% +$851K 0.27% 50
2023
Q2
$4.66M Sell
34,557
-7,612
-18% -$1.12M 0.21% 62
2023
Q1
$6.72M Buy
42,169
+1,610
+4% +$246K 0.34% 39
2022
Q4
$6.55M Sell
40,559
-10,660
-21% -$1.63M 0.37% 39
2022
Q3
$6.87M Buy
51,219
+13,193
+35% +$1.89M 0.37% 29
2022
Q2
$5.82M Sell
38,026
-6,819
-15% -$1.04M 0.37% 24
2022
Q1
$7.27M Buy
44,845
+33,021
+279% +$4.8M 0.49% 27
2021
Q4
$1.6M Buy
11,824
+2,083
+21% +$246K 0.1% 102
2021
Q3
$1.05M Sell
9,741
-205
-2% -$23.4K 0.07% 133
2021
Q2
$1.12M Buy
9,946
+215
+2% +$24.2K 0.08% 121
2021
Q1
$1.05M Buy
9,731
+2,565
+36% +$274K 0.09% 106
2020
Q4
$768K Buy
7,166
+2,330
+48% +$224K 0.07% 114
2020
Q3
$424K Buy
4,836
+830
+21% +$78.1K 0.05% 158
2020
Q2
$393K Buy
+4,006
New +$353K 0.05% 139
2020
Q1
Sell
-6,691
Closed -$592K 179
2019
Q4
$592K Buy
6,691
+867
+15% +$72K 0.09% 75
2019
Q3
$441K Buy
5,824
+353
+6% +$24.2K 0.07% 80
2019
Q2
$398K Buy
5,471
+173
+3% +$13.6K 0.07% 85
2019
Q1
$427K Sell
5,298
-190
-3% -$15.5K 0.08% 82
2018
Q4
$506K Buy
5,488
+413
+8% +$36.3K 0.11% 62
2018
Q3
$480K Buy
5,075
+227
+5% +$21.5K 0.12% 63
2018
Q2
$449K Buy
4,848
+130
+3% +$12.7K 0.12% 64
2018
Q1
$447K Sell
4,718
-232
-5% -$25.5K 0.13% 62
2017
Q4
$479K Buy
+4,950
New +$467K 0.14% 69

Other funds holding ABBV

Ritholtz Wealth Management's ABBV Position: Q2 2026 in Review

Ritholtz Wealth Management increased its AbbVie (ABBV) stake by 3.2% in Q2 2026, buying an estimated $334K and bringing the position to 49,487 shares worth $12.5M. The position accounts for 0.19% of the portfolio, ranked #66.

Ritholtz Wealth Management first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Ritholtz Wealth Management held 49,487 shares of AbbVie worth $12.5M as of Q2 2026.
  • Ritholtz Wealth Management bought 1,552 AbbVie shares in Q2 2026, an estimated $334K.
  • AbbVie made up 0.19% of Ritholtz Wealth Management's portfolio in Q2 2026, its #66 holding.
  • Ritholtz Wealth Management first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ritholtz Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.